Vuoi passare al contenuto? Vai ai contenuti
Convatec Group Contact Us България България Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Österreich Österreich Schweiz (Deutsch) Schweiz (Deutsch) Deutschland Deutschland Ελλάδα Ελλάδα United Kingdom United Kingdom Ireland Ireland España España Eesti Eesti Suomi Suomi Suisse (Français) Suisse (Français) France France Hrvatska Hrvatska Magyarország Magyarország Ísland Ísland Italia Italia Lietuva Lietuva Latvija Latvija Северна Македонија Северна Македонија Malta Malta Norge Norge België België Nederland Nederland Polska Polska Portugal Portugal România România Slovensko Slovensko Slovenija Slovenija Srbija Srbija Sverige Sverige Türkiye Türkiye Україна Україна Brasil Brasil United States (English) United States (English) Estados Unidos (Español) Estados Unidos (Español) Argentina Argentina Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Ecuador Ecuador México México Perú Perú Belize Belize Guyana Guyana Jamaica Jamaica Venezuela Venezuela Costa Rica Costa Rica Curaçao Curaçao República Dominicana República Dominicana Guatemala Guatemala Honduras Honduras Nicaragua Nicaragua Panamá Panamá Puerto Rico Puerto Rico Suriname Suriname El Salvador El Salvador الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين مصر مصر ישראל ישראל ایران ایران الأردن الأردن عُمان عُمان قطر قطر پاکستان پاکستان لبنان لبنان الكويت الكويت المملكة العربية السعودية المملكة العربية السعودية Suid-Afrika Suid-Afrika العراق العراق Australia Australia India India Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Indonesia Indonesia 日本 日本 대한민국 대한민국 ไทย ไทย Việt Nam Việt Nam 中国大陆 中国大陆 中国香港特别行政区 中国香港特别行政区 中国台湾 中国台湾
False /oidc-signin/it-it/ Convatec Group Contact Us България България Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Österreich Österreich Schweiz (Deutsch) Schweiz (Deutsch) Deutschland Deutschland Ελλάδα Ελλάδα United Kingdom United Kingdom Ireland Ireland España España Eesti Eesti Suomi Suomi Suisse (Français) Suisse (Français) France France Hrvatska Hrvatska Magyarország Magyarország Ísland Ísland Italia Italia Lietuva Lietuva Latvija Latvija Северна Македонија Северна Македонија Malta Malta Norge Norge België België Nederland Nederland Polska Polska Portugal Portugal România România Slovensko Slovensko Slovenija Slovenija Srbija Srbija Sverige Sverige Türkiye Türkiye Україна Україна Brasil Brasil United States (English) United States (English) Estados Unidos (Español) Estados Unidos (Español) Argentina Argentina Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Ecuador Ecuador México México Perú Perú Belize Belize Guyana Guyana Jamaica Jamaica Venezuela Venezuela Costa Rica Costa Rica Curaçao Curaçao República Dominicana República Dominicana Guatemala Guatemala Honduras Honduras Nicaragua Nicaragua Panamá Panamá Puerto Rico Puerto Rico Suriname Suriname El Salvador El Salvador الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين مصر مصر ישראל ישראל ایران ایران الأردن الأردن عُمان عُمان قطر قطر پاکستان پاکستان لبنان لبنان الكويت الكويت المملكة العربية السعودية المملكة العربية السعودية Suid-Afrika Suid-Afrika العراق العراق Australia Australia India India Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Indonesia Indonesia 日本 日本 대한민국 대한민국 ไทย ไทย Việt Nam Việt Nam 中国大陆 中国大陆 中国香港特别行政区 中国香港特别行政区 中国台湾 中国台湾

Terapia infusionale

Aree terapeutiche per l’infusione sottocutanea con set per infusione neria™
;

Aree terapeutiche per l’infusione sottocutanea con set per infusione neria™

I set per infusione neria™ sono dispositivi per infusione sottocutanea testati in-vitro e approvati per l’infusione di farmaci nel trattamento della malattia di Parkinson1, della talassemia2 e dell’immunodeficienza primitiva3 e nella gestione del dolore4,5

Maggiori informazioni sui set per infusione neria™ sono disponibili qui

Somministrazione sottocutanea del farmaco 

L’infusione sottocutanea rilascia il farmaco per un periodo prolungato nel tessuto adiposo sotto la cute, dove viene assorbito dall’organismo. La procedura prevede l’inserimento nella pelle di un ago collegato a una catetere morbido. L’ago o il catetere viene poi lasciato nel tessuto per un tempo variabile, da poche ore fino a 72 ore. Aghi e cannule possono variare in lunghezza, dimensioni, caratteristiche e metodo di inserimento. I set per infusione eliminano la necessità di una o più iniezioni giornaliere di un farmaco specifico.

1 Stability test and function test of Comfort and Contact Detach by means of the medicament APO-go. Analysis report no. 294690. January 14-April 1, 2009. Data on file. Unomedical.
2 Drug Device Stability Test Thalaset – Study Desferal (deferoxamine mesilate). July 1, 2005. Data on file. Unomedical.
3 Compatibility and stability testing of the catheter device Unomedical comfort™ with the immunoglobulin Subcuvia. IKFE 09016. April 16, 2009. Data on file. Unomedical.
4 Drug Compatibility Study of Three Infusion Devices with Morphine Sulfate, version 1.4, IKFE 10006, September 2, 2011, Data on File. Unomedical.
5 Drug Compatibility Study of Three Infusion Devices with Hydromorphone Hydrochloride, version 1.4, IKFE 10006, September 2, 2011, Data on File. Unomedical.

Stai per lasciare convatec.com

Questo sito Internet può fornire link o riferimenti ad altri siti, ma Convatec non ha alcuna responsabilità per il contenuto di tali siti e non sarà responsabile per eventuali danni o lesioni derivanti da tale contenuto. I link ad altri siti sono forniti solo per comodità agli utenti di questo sito Internet.

Continuare?